FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme (Q37629395)
scientific article
Language:
Current Data About FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
(P31) (Q13442814)
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P304) 1131-1138
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P433) 11
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P478) 14
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P577) Friday, November 6, 2009
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P921) (Q42214612)

(Q413299)
(P887)

(Q282142)
(P887)

(P1433) (Q2122327)
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P1476) "FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme" (language: en)
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

(P2093) Martin H Cohen
(P1545) 1
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

Yuan Li Shen
(P1545) 2
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

Patricia Keegan
(P1545) 3
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

Richard Pazdur
(P1545) 4
(P248)
(P698) 19897538
(P813) Monday, August 21, 2017

other details
description scientific article

External Links
(P356) 10.1634/THEONCOLOGIST.2009-0121
(P698) 19897538
(P5875) 38074769